Literature DB >> 32064507

"Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.

Rajan Jain1, Derek R Johnson2, Sohil H Patel3, Mauricio Castillo4, Marion Smits5, Martin J van den Bent6, Andrew S Chi7, Daniel P Cahill8.   

Abstract

AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate dehydrogenase (IDH)-mutant 1p/19q non-codeleted gliomas. Multiple independent studies show that the T2-FLAIR mismatch sign has near-perfect specificity, but low sensitivity for diagnosing IDH-mutant astrocytomas. Thus, the T2-FLAIR mismatch sign represents a non-invasive radiogenomic diagnostic finding with potential clinical impact. Recently, false positive cases have been reported, many related to variable application of the sign's imaging criteria and differences in image acquisition, as well as to differences in the included patient populations. Here we summarize the imaging criteria for the T2-FLAIR mismatch sign, review similarities and differences between the multiple validation studies, outline strategies to optimize its clinical use, and discuss potential opportunities to refine imaging criteria in order to maximize its impact in glioma diagnostics.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IDH; T2-FLAIR mismatch; genomics; glioma; glioma imaging; radiogenomics

Mesh:

Substances:

Year:  2020        PMID: 32064507      PMCID: PMC7339896          DOI: 10.1093/neuonc/noaa041

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  35 in total

1.  Routine clinical brain MRI sequences for use at 3.0 Tesla.

Authors:  Hanzhang Lu; Lidia M Nagae-Poetscher; Xavier Golay; Doris Lin; Martin Pomper; Peter C M van Zijl
Journal:  J Magn Reson Imaging       Date:  2005-07       Impact factor: 4.813

2.  T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.

Authors:  Sohil H Patel; Laila M Poisson; Daniel J Brat; Yueren Zhou; Lee Cooper; Matija Snuderl; Cheddhi Thomas; Ana M Franceschi; Brent Griffith; Adam E Flanders; John G Golfinos; Andrew S Chi; Rajan Jain
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  MRI Features Can Predict 1p/19q Status in Intracranial Gliomas.

Authors:  A Lasocki; F Gaillard; A Gorelik; M Gonzales
Journal:  AJNR Am J Neuroradiol       Date:  2018-03-08       Impact factor: 3.825

4.  Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas.

Authors:  Y W Park; K Han; S S Ahn; S Bae; Y S Choi; J H Chang; S H Kim; S-G Kang; S-K Lee
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-09       Impact factor: 3.825

5.  Probabilistic radiographic atlas of glioblastoma phenotypes.

Authors:  B M Ellingson; A Lai; R J Harris; J M Selfridge; W H Yong; K Das; W B Pope; P L Nghiemphu; H V Vinters; L M Liau; P S Mischel; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2012-09-20       Impact factor: 3.825

6.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

Authors:  Michael D Jenkinson; Daniel G du Plessis; Trevor S Smith; Kathy A Joyce; Peter C Warnke; Carol Walker
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

Review 7.  Correlations between molecular profile and radiologic pattern in oligodendroglial tumors.

Authors:  F Laigle-Donadey; N Martin-Duverneuil; J Lejeune; E Crinière; L Capelle; H Duffau; P Cornu; P Broët; M Kujas; K Mokhtari; A Carpentier; M Sanson; K Hoang-Xuan; J Thillet; J Y Delattre
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

8.  Fluid-attenuated inversion recovery ring sign as a marker of dysembryoplastic neuroepithelial tumors.

Authors:  Hemant A Parmar; Cynthia Hawkins; Rodrigo Ozelame; Sylvester Chuang; James Rutka; Susan Blaser
Journal:  J Comput Assist Tomogr       Date:  2007 May-Jun       Impact factor: 1.826

9.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

Review 10.  Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.

Authors:  Thomas Leather; Michael D Jenkinson; Kumar Das; Harish Poptani
Journal:  Metabolites       Date:  2017-06-19
View more
  24 in total

1.  Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Authors:  Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

2.  Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas.

Authors:  S Mohammed; V Ravikumar; E Warner; S H Patel; S Bakas; A Rao; R Jain
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-11       Impact factor: 3.825

3.  T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls.

Authors:  Catarina Pinto; Carolina Noronha; Ricardo Taipa; Cristina Ramos
Journal:  Br J Radiol       Date:  2021-10-07       Impact factor: 3.039

4.  MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.

Authors:  David A Joyner; John Garrett; Prem P Batchala; Bharath Rama; Joshua R Ravicz; James T Patrie; Maria-B Lopes; Camilo E Fadul; David Schiff; Rajan Jain; Sohil H Patel
Journal:  Neuroradiology       Date:  2022-08-12       Impact factor: 2.995

5.  Glioblastoma in Patients With Multiple Sclerosis.

Authors:  Jillian M Berkman; Vihang Nakhate; L Nicolas Gonzalez Castro
Journal:  Neurohospitalist       Date:  2022-06-08

6.  Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.

Authors:  Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain
Journal:  J Neurooncol       Date:  2021-03-04       Impact factor: 4.130

Review 7.  Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.

Authors:  Takashi Komori
Journal:  Lab Invest       Date:  2021-09-09       Impact factor: 5.662

Review 8.  Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.

Authors:  Daniel P Cahill
Journal:  Neurosurg Clin N Am       Date:  2020-11-05       Impact factor: 2.509

9.  Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.

Authors:  Jun Zhang; Hong Peng; Yu-Lin Wang; Hua-Feng Xiao; Yuan-Yuan Cui; Xiang-Bing Bian; De-Kang Zhang; Lin Ma
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

10.  BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas.

Authors:  Petros D Petridis; Craig I Horenstein; Brianna Pereira; Peter B Wu; Jorge Samanamud; Tamara Marie; Deborah Boyett; Tejaswi D Sudhakar; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Peter Canoll; Jack Grinband
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.